1. A 58-year-old man with established coronary artery disease has been on simvastatin 40 mg daily for two years with good LDL-C control. He is admitted with severe community-acquired pneumonia and started on clarithromycin. On day 6, he develops diffuse muscle pain and weakness; creatine kinase is 18,400 U/L and creatinine has risen from 1.1 to 2.4 mg/dL. Which of the following best explains the mechanism responsible for this presentation?
A) Clarithromycin inhibits the organic anion-transporting polypeptide 1B1 (OATP1B1) hepatic uptake transporter, preventing simvastatin delivery into hepatocytes and causing accumulation in the systemic circulation at concentrations sufficient to produce rhabdomyolysis
B) Clarithromycin is a strong inhibitor of cytochrome P450 3A4 (CYP3A4), the primary metabolic pathway for simvastatin; co-administration impairs simvastatin first-pass clearance and increases systemic exposure by 5- to 20-fold, producing toxic skeletal muscle concentrations that cause rhabdomyolysis
C) Clarithromycin inhibits glucuronidation pathways responsible for simvastatin lactone elimination, producing a 3- to 4-fold increase in systemic exposure through a mechanism equivalent to gemfibrozil co-administration
D) Clarithromycin inhibits CYP2C9, the isoform responsible for simvastatin metabolism, producing a moderate exposure increase that is compounded by the acute kidney injury from pneumonia-related hypoperfusion
E) Clarithromycin produces a pharmacodynamic interaction at the mitochondrial respiratory chain, directly impairing skeletal muscle oxidative phosphorylation independently of any change in simvastatin plasma concentration
ANSWER: B
Rationale:
This question asked you to identify the mechanism by which a strong CYP3A4 inhibitor produces life-threatening toxicity in a patient on simvastatin. Simvastatin is almost entirely dependent on CYP3A4 for first-pass hepatic metabolism; the enzyme converts the active hydroxy acid and its prodrug precursor into inactive biliary metabolites. Clarithromycin is one of the most potent clinically available CYP3A4 inhibitors, and by blocking this pathway it prevents simvastatin from being cleared during its first pass through the liver, producing 5- to 20-fold increases in systemic statin exposure. The resulting toxic skeletal muscle concentrations overwhelm mitochondrial coenzyme Q10-dependent pathways that maintain myocyte energy metabolism, producing the clinical syndrome of rhabdomyolysis — diffuse myalgias, creatine kinase exceeding 10,000 U/L, and myoglobin-driven acute kidney injury, all present in this case. This interaction is the basis for the FDA contraindication of simvastatin and lovastatin with strong CYP3A4 inhibitors.
Option A: Option A is incorrect because OATP1B1 inhibition is the mechanism by which cyclosporine and gemfibrozil increase statin exposure — clarithromycin's dominant interaction mechanism is CYP3A4 inhibition, not transporter blockade.
Option C: Option C is incorrect because glucuronidation inhibition is gemfibrozil's mechanism for elevating statin lactone exposure — clarithromycin does not act through this pathway, and the 3- to 4-fold exposure increase described is far below the magnitude of CYP3A4-mediated interaction with simvastatin.
Option D: Option D is incorrect because simvastatin is metabolized by CYP3A4, not CYP2C9; CYP2C9 is the relevant isoform for fluvastatin and partially for rosuvastatin, and even a true CYP2C9 interaction would produce only moderate exposure increases insufficient to explain rhabdomyolysis at standard doses.
Option E: Option E is incorrect because there is no established pharmacodynamic interaction between clarithromycin and the mitochondrial respiratory chain — the toxicity here is entirely pharmacokinetic in origin, driven by impaired simvastatin clearance.
2. A 67-year-old woman with stable coronary artery disease has been on atorvastatin 40 mg daily for three years. Her most recent LDL-C is 78 mg/dL, just above her target of less than 70 mg/dL. Her cardiologist considers escalating to atorvastatin 80 mg. Which of the following best characterizes the expected pharmacological outcome of this dose escalation and the most appropriate clinical interpretation?
A) Doubling the atorvastatin dose from 40 to 80 mg will produce an approximately 25% additional absolute reduction in LDL-C because statin dose-response follows a linear relationship at higher doses, and the incremental benefit of escalating above 40 mg is proportionally greater than at lower doses
B) Escalating to atorvastatin 80 mg is appropriate and will produce approximately 18 to 20% additional absolute LDL-C reduction — equivalent to the expected benefit of adding ezetimibe — making dose escalation the preferred intensification strategy before adding a second agent
C) Atorvastatin 80 mg should be avoided in this patient because the high-intensity dose classification applies only to patients with LDL-C above 190 mg/dL at baseline; for patients already near target on moderate-intensity therapy, guidelines recommend against escalating to high-intensity dosing due to adverse effect burden
D) Doubling the atorvastatin dose from 40 to 80 mg will produce approximately 6% additional absolute LDL-C reduction — a modest increment explained by the log-linear dose-response relationship of HMG-CoA reductase inhibition — making the addition of ezetimibe a pharmacologically more efficient strategy to close the remaining gap to target
E) The dose escalation will produce no meaningful additional LDL-C reduction because atorvastatin 40 mg already achieves near-complete HMG-CoA reductase inhibition in hepatocytes, and any further dose increase is constrained entirely by receptor saturation
ANSWER: D
Rationale:
This question asked you to apply the rule of 6s to a common clinical dose-escalation decision. HMG-CoA reductase inhibition by statins follows a log-linear dose-response curve: each doubling of the dose from any point on the curve produces approximately 6% additional absolute LDL-C reduction. This relationship has direct clinical consequences — a patient achieving 43% LDL-C reduction on atorvastatin 40 mg will achieve approximately 49% on atorvastatin 80 mg, an increment of roughly 5 to 8 mg/dL at the LDL-C levels relevant to this patient. This small additional reduction comes at the cost of meaningfully increased adverse effect risk at the 80 mg dose. By contrast, adding ezetimibe — which inhibits intestinal cholesterol absorption via the NPC1L1 transporter by a complementary and entirely non-overlapping mechanism — typically produces an additional 18 to 20% LDL-C reduction on top of any background statin. Ezetimibe is therefore the pharmacologically more efficient strategy when a patient is near but not at target on maximally tolerated statin, and is the intensification approach endorsed in the 2018 ACC/AHA guideline.
Option A: Option A is incorrect because statin dose-response is log-linear, not linear; the 25% figure reflects a fundamental misunderstanding of the pharmacodynamic relationship and would dramatically overestimate the benefit of dose escalation.
Option B: Option B is incorrect because 18 to 20% additional reduction from atorvastatin dose doubling is not achievable by the rule of 6s — that figure describes the expected incremental benefit from ezetimibe, not from statin dose escalation.
Option C: Option C is incorrect because high-intensity statin therapy is indicated by cardiovascular risk category, not by baseline LDL-C threshold; atorvastatin 80 mg is guideline-recommended in secondary prevention patients regardless of baseline LDL-C, and the option mischaracterizes both the indication criteria and guideline intent.
Option E: Option E is incorrect because receptor saturation is not the limiting factor at atorvastatin 40 mg; the log-linear dose-response is a pharmacokinetic and enzyme-kinetic property, and meaningful additional HMG-CoA reductase inhibition does occur at 80 mg — the point is that the increment is modest by design of the pharmacological relationship.
3. A 54-year-old man with hypertension and type 2 diabetes presents with an anterior ST-elevation myocardial infarction and undergoes successful primary percutaneous coronary intervention. His admission LDL-C is 61 mg/dL. He has never been on a statin. The intern notes that his LDL-C is already below 70 mg/dL and questions whether statin initiation is necessary. Which of the following responses is pharmacologically most accurate?
A) High-intensity statin therapy should be initiated within 24 hours of ACS presentation regardless of baseline LDL-C level; the early benefit in ACS is driven substantially by pleiotropic effects — anti-inflammatory action via NF-κB suppression, endothelial nitric oxide synthase upregulation, and antithrombotic effects on platelet aggregability — that operate independently of and precede meaningful LDL-C reduction, and current guidelines make no LDL-C threshold below which initiation is withheld in this setting
B) The intern is correct that initiation can be deferred; guidelines recommend reassessing at 6 weeks on lifestyle modification before introducing pharmacotherapy in patients with ACS whose LDL-C is already below 70 mg/dL, given that cardiovascular benefit of statins at this LDL-C level has not been established in randomized trials
C) Statin initiation should be deferred until 4 to 6 weeks post-ACS to allow the acute inflammatory milieu to resolve; early initiation within the first 24 to 48 hours has been associated with paradoxical increases in peri-procedural myocardial injury in randomized trials
D) A moderate-intensity statin such as pravastatin 40 mg is appropriate given this patient's already-low LDL-C; high-intensity statins are reserved for ACS patients presenting with LDL-C above 100 mg/dL
E) Statin initiation should be deferred in this patient because his diabetes substantially elevates statin-associated myopathy risk, and the benefit-risk ratio does not support statin use in diabetic ACS patients who are statin-naive with a presenting LDL-C below 70 mg/dL
ANSWER: A
Rationale:
This question asked you to apply the pharmacological rationale and guideline recommendation for statin initiation in the ACS setting, specifically testing the principle that the indication is unconditional with respect to presenting LDL-C. High-intensity statin initiation in ACS is indicated regardless of baseline LDL-C level, regardless of prior statin use, and regardless of comorbidities including diabetes. The pharmacological basis is that the early benefit of statins in ACS — evident as event curve separation within 30 days in the PROVE IT–TIMI 22 trial — is not mediated by LDL-C reduction, which requires weeks to months for its full magnitude. Instead, rapid anti-inflammatory effects via inhibition of Rho GTPase prenylation and downstream NF-κB signaling, improved endothelial function through eNOS upregulation within days, and modest antithrombotic effects on platelet aggregability and tissue factor expression in the destabilized plaque collectively produce early benefit that is independent of LDL-C achieved. Current ACC/AHA guidelines recommend initiating atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg within 24 hours of ACS presentation in all patients.
Option B: Option B is incorrect because guideline-directed statin therapy in ACS is not contingent on presenting LDL-C; deferring initiation in a patient with LDL-C of 61 mg/dL represents a clinical error inconsistent with the evidence base and guideline recommendations.
Option C: Option C is incorrect because early statin initiation — within the first 24 to 48 hours — is specifically supported by the evidence including PROVE IT–TIMI 22, which initiated atorvastatin within 10 days of ACS; no randomized trial has demonstrated paradoxical peri-procedural harm from early statin initiation.
Option D: Option D is incorrect because ACS mandates high-intensity therapy unconditionally; prescribing a moderate-intensity agent based on a low presenting LDL-C is a clinically significant downgrade from the guideline standard of care.
Option E: Option E is incorrect because diabetes is not a contraindication to statin use — statins are strongly indicated in diabetic patients with cardiovascular disease, and statin-associated myopathy risk at standard doses is not substantially elevated in patients with type 2 diabetes compared to the general population.
4. A 71-year-old woman with stage 4 chronic kidney disease (eGFR 22 mL/min/1.73m²) requires statin initiation for an LDL-C of 112 mg/dL and a 10-year ASCVD risk of 18%. Her nephrologist asks which statin and dose is most appropriate given her renal function. Which of the following prescribing decisions is most consistent with established pharmacokinetic and safety data for this population?
A) Atorvastatin 40 mg daily, which requires no dose adjustment in any stage of CKD because its elimination is almost entirely biliary with negligible renal excretion, making it pharmacokinetically indifferent to eGFR
B) Pravastatin 40 mg daily, which is the only statin with a fully established safety record in severe CKD because its hydrophilic properties prevent entry into skeletal muscle, eliminating myopathy risk entirely in patients with reduced renal function
C) Simvastatin 40 mg daily, which is preferred in advanced CKD because complete hepatic first-pass metabolism with no renal excretion component makes it the safest statin in patients with eGFR below 30 mL/min/1.73m²
D) Rosuvastatin 20 to 40 mg daily, which is the preferred agent because its hydrophilic properties and absence of CYP3A4 metabolism produce a clean pharmacokinetic profile that eliminates the need for any dose adjustment regardless of the degree of renal impairment
E) Rosuvastatin 10 mg daily, with the dose capped at this level because renal excretion contributes a proportionally greater share of rosuvastatin elimination than for other statins, producing significantly elevated plasma concentrations in patients with eGFR below 30 mL/min/1.73m², and the FDA prescribing information specifies a 10 mg dose maximum in this population
ANSWER: E
Rationale:
This question asked you to apply pharmacokinetic knowledge of rosuvastatin to a prescribing decision in severe chronic kidney disease. Rosuvastatin is hydrophilic with minimal CYP-mediated metabolism — properties that give it a generally favorable drug interaction profile — but unlike atorvastatin, which is primarily eliminated in bile with negligible renal excretion, rosuvastatin has a proportionally greater contribution from renal elimination. In patients with severe CKD (eGFR below 30 mL/min/1.73m²), impaired renal clearance results in significantly elevated rosuvastatin plasma concentrations. The FDA prescribing information therefore caps the rosuvastatin dose at 10 mg in this population and recommends against the 20 and 40 mg doses. Rosuvastatin 10 mg still achieves moderate-intensity LDL-C reduction and, combined with its non-CYP metabolism, avoids the interaction risks of CYP3A4-metabolized statins in a population typically on multiple medications.
Option A: Option A is incorrect as the best answer: while atorvastatin's biliary elimination and absence of dose adjustment requirements in CKD are accurately described, the option fails to account for rosuvastatin at the FDA-specified dose cap of 10 mg, which is explicitly endorsed for severe CKD and is the most precisely correct answer for this population.
Option B: Option B is incorrect because pravastatin's hydrophilic properties do not eliminate myopathy risk entirely in any population; hydrophilicity reduces but does not abolish skeletal muscle penetration, and pravastatin's documented safety in transplant recipients reflects its non-CYP profile in a drug-interaction context, not universal myopathy immunity in CKD.
Option C: Option C is incorrect because simvastatin carries the highest CYP3A4 drug interaction risk of any widely prescribed statin, and its 80 mg dose is restricted even in patients without CKD — it is not the safest statin in advanced CKD and is largely supplanted by atorvastatin and rosuvastatin for high-intensity therapy.
Option D: Option D is incorrect because rosuvastatin does require dose adjustment in severe CKD; its hydrophilicity and non-CYP metabolism do not protect against accumulation when renal elimination is impaired, and the claim that no adjustment is needed regardless of eGFR contradicts the FDA label.
5. A 62-year-old man with coronary artery disease on rosuvastatin 20 mg daily has a triglyceride level of 390 mg/dL. His cardiologist decides to add a fibrate. Which of the following choices of fibrate and rationale is most consistent with established pharmacological evidence regarding statin-fibrate combination safety?
A) Gemfibrozil is preferred over fenofibrate because gemfibrozil more potently activates peroxisome proliferator-activated receptor alpha (PPARα), producing superior triglyceride lowering and a more favorable net cardiovascular risk reduction when added to statin therapy
B) Gemfibrozil is preferred specifically with rosuvastatin because rosuvastatin's renal elimination pathway is unaffected by gemfibrozil's hepatic enzyme inhibition, making this combination uniquely safe compared to gemfibrozil combined with lipophilic statins metabolized by CYP3A4
C) Fenofibrate is the preferred fibrate for combination with a statin because, unlike gemfibrozil, fenofibrate does not meaningfully inhibit the OATP1B1 hepatic uptake transporter or the glucuronidation pathways responsible for statin lactone elimination, and therefore does not substantially increase statin plasma exposure or myopathy risk
D) Both gemfibrozil and fenofibrate carry equivalent myopathy risk when combined with rosuvastatin because rosuvastatin's hydrophilic properties and absence of CYP3A4 metabolism render it pharmacokinetically immune to the interaction mechanisms underlying fibrate-statin myopathy
E) Fenofibrate should be avoided in this patient because it is a potent CYP3A4 inhibitor that will substantially increase rosuvastatin systemic exposure, producing myopathy risk equivalent to that seen with clarithromycin-statin combinations
ANSWER: C
Rationale:
This question asked you to distinguish between gemfibrozil and fenofibrate as statin combination partners based on their different pharmacokinetic interaction profiles. Gemfibrozil is a potent dual inhibitor of two critical statin clearance pathways: it inhibits the OATP1B1 hepatic uptake transporter, which delivers statins from portal blood into hepatocytes for metabolism; and it inhibits the UGT glucuronidation enzymes that convert statin lactone forms into inactive metabolites for elimination. By blocking both pathways simultaneously, gemfibrozil substantially increases systemic statin exposure across virtually all statins, producing a myopathy and rhabdomyolysis risk that is consistently higher in pharmacovigilance data and clinical trial safety analyses than fenofibrate-statin combinations. Fenofibrate is a PPARα agonist that does not meaningfully inhibit OATP1B1 or glucuronidation at therapeutic doses — its myopathy risk in statin combination is substantially lower, and it is the fibrate endorsed in clinical guidelines when combination lipid-lowering therapy is indicated.
Option A: Option A is incorrect because fibrate selection for statin combination is driven entirely by pharmacokinetic interaction profile, not by comparative PPARα potency; gemfibrozil's superior myopathy risk profile disqualifies it as the preferred combination partner regardless of triglyceride-lowering efficacy relative to fenofibrate.
Option B: Option B is incorrect because gemfibrozil's OATP1B1 inhibition affects rosuvastatin hepatic uptake regardless of rosuvastatin's renal elimination component — elevated systemic rosuvastatin concentrations from transporter blockade increase myopathy risk, and this is not uniquely safe; rosuvastatin relies on OATP1B1 for hepatic uptake and is not protected by its hydrophilicity from this interaction.
Option D: Option D is incorrect because rosuvastatin is not immune to fibrate-statin pharmacokinetic interactions — rosuvastatin's OATP1B1 dependence means gemfibrozil raises its plasma exposure meaningfully, and hydrophilicity does not confer protection against transporter-mediated interactions.
Option E: Option E is incorrect because fenofibrate is not a CYP3A4 inhibitor; its clearance is primarily renal glucuronidation and it produces no clinically meaningful CYP3A4 inhibition — the comparison to clarithromycin is pharmacologically unfounded.
6. A 49-year-old man with no prior cardiovascular events has an LDL-C of 118 mg/dL and a 10-year ASCVD risk of 6.2%, below the conventional 7.5% threshold for initiating a statin discussion. However, his high-sensitivity C-reactive protein (hsCRP) is 3.8 mg/L on two separate measurements. His physician considers whether this finding alters the statin initiation decision. Which of the following best characterizes the clinical and pharmacological evidence informing this decision?
A) Elevated hsCRP has no established role in statin initiation decisions because the JUPITER trial was terminated early for benefit — a design feature that systematically overestimates treatment effects — and subsequent analyses have not confirmed a mortality benefit from statins in primary prevention patients with normal LDL-C
B) Rosuvastatin reduces hsCRP through direct inhibition of interleukin-6 synthesis in hepatocytes, a mechanism entirely independent of LDL-C lowering; because JUPITER's benefit cannot be attributed to LDL-C reduction, its findings apply only to patients with documented systemic inflammatory conditions and not to otherwise healthy adults with incidentally elevated hsCRP
C) The ACC/AHA guideline on blood cholesterol management does not incorporate hsCRP into statin initiation decisions; inflammatory biomarkers remain investigational and statin therapy should be deferred until this patient's 10-year ASCVD risk exceeds 7.5% based on traditional risk factors alone
D) The JUPITER trial enrolled 17,802 adults with LDL-C below 130 mg/dL and hsCRP of 2.0 mg/L or higher and demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% and all-cause mortality by 20%; this evidence led the 2018 ACC/AHA guideline to designate hsCRP of 2.0 mg/L or higher as a risk-enhancing factor that supports statin initiation in patients with borderline or intermediate ASCVD risk, making this patient's hsCRP of 3.8 mg/L clinically actionable
E) Because this patient's LDL-C is below 130 mg/dL, statin therapy would produce no cardiovascular risk reduction regardless of hsCRP; the Heart Protection Study established that statin benefit requires a baseline LDL-C above 3.0 mmol/L (116 mg/dL), and this patient does not meet that threshold
ANSWER: D
Rationale:
This question asked you to apply the JUPITER trial evidence and its guideline incorporation to a primary prevention patient with elevated hsCRP and below-threshold ASCVD risk. The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER, 2008) enrolled patients specifically excluded from statin therapy under traditional LDL-C-based criteria — healthy adults with LDL-C below 130 mg/dL but hsCRP of 2.0 mg/L or higher. Rosuvastatin 20 mg reduced the primary composite cardiovascular endpoint by 44% and all-cause mortality by 20% versus placebo, with the trial stopped early after a median 1.9 years due to the magnitude of benefit. This trial directly informed the 2018 ACC/AHA guideline, which incorporated hsCRP of 2.0 mg/L or higher as one of several risk-enhancing factors that can appropriately shift the statin initiation decision toward treatment in patients with borderline (5–7.5%) or intermediate (7.5–20%) 10-year ASCVD risk. This patient's hsCRP of 3.8 mg/L on two measurements clearly exceeds the 2.0 mg/L threshold and constitutes an appropriate basis for a statin initiation discussion. Option E misrepresents the Heart Protection Study, which demonstrated the opposite of a minimum LDL-C threshold requirement: HPS showed that statin benefit extended to patients with baseline LDL-C below 3.0 mmol/L (116 mg/dL), challenging the concept of a threshold and expanding — not restricting — the population eligible for statin therapy.
Option A: Option A is incorrect because while early trial termination is a recognized methodological concern, the all-cause mortality reduction in JUPITER is a hard clinical endpoint not artifactually inflated by stopping rules in the way that surrogate outcomes would be; updated CTT meta-analyses confirm cardiovascular event reduction with statins across the primary prevention risk spectrum.
Option B: Option B is incorrect in its mechanistic claim — rosuvastatin reduces hsCRP via Rho GTPase prenylation inhibition and downstream NF-κB suppression, not through direct IL-6 synthesis inhibition; and the restriction of JUPITER's applicability only to patients with documented inflammatory conditions is not supported by the trial enrollment criteria or guideline interpretation.
Option C: Option C is incorrect because the 2018 ACC/AHA guideline explicitly includes hsCRP of 2.0 mg/L or higher as a risk-enhancing factor — it is part of the current standard decision framework, not an investigational biomarker.
7. A 61-year-old man with a myocardial infarction three years ago was on atorvastatin 80 mg with LDL-C well controlled at 54 mg/dL. After reading material attributing his fatigue to statins, he self-discontinued eight weeks ago. He now presents after a non-fatal MI with LDL-C of 138 mg/dL. Which of the following best explains the pharmacological mechanisms underlying the elevated cardiovascular risk associated with abrupt statin discontinuation in patients with established ASCVD?
A) Loss of pleiotropic plaque-stabilizing and anti-inflammatory statin effects combined with upregulation of PCSK9 expression — which occurs as rising intracellular cholesterol stimulates PCSK9 production and accelerates LDL receptor degradation — creates an acute cardiovascular vulnerability window; population-based data consistently show substantially higher rates of recurrent MI and death in post-MI patients who discontinue statins compared to those who continue
B) Abrupt statin discontinuation causes rebound overexpression of HMG-CoA reductase that transiently elevates LDL-C to 40 to 60% above the pre-statin baseline because compensatory enzyme upregulation during statin therapy is not immediately reversible, producing a surge in atherogenic lipoprotein flux that exceeds the pre-treatment state
C) Statin withdrawal triggers acute rebound of thromboxane A2 synthesis above pre-treatment levels due to suppression of prostaglandin feedback pathways during statin therapy, producing a prothrombotic state pharmacologically equivalent to aspirin discontinuation in high-risk patients
D) Statin discontinuation in patients with established CAD predictably causes cholesterol crystal embolization from destabilized plaques within 4 to 6 weeks, because fibrous cap thickness maintained by statin-driven macrophage suppression cannot be sustained once plaque-stabilizing therapy is withdrawn
E) The risk of statin discontinuation is entirely attributable to the rise in LDL-C itself and is equivalent in magnitude and time course to the benefit achieved when the same statin is initiated — making the sole clinical priority to resume the original agent at the original dose as rapidly as possible
ANSWER: A
Rationale:
This question asked you to identify the pharmacological mechanisms responsible for the elevated cardiovascular risk following statin discontinuation in established ASCVD — a phenomenon sometimes termed statin rebound. The correct answer describes two distinct and well-characterized mechanisms, both written into option A. First, loss of pleiotropic effects: the anti-inflammatory suppression of NF-κB signaling, eNOS-mediated endothelial stabilization, and plaque-stabilizing reduction of macrophage infiltration and fibrous cap thinning are all rapidly lost when statin therapy stops — these effects were actively maintaining plaque stability independent of LDL-C and cannot be sustained without the drug. Second, PCSK9 upregulation: as statin inhibition of the mevalonate pathway is removed, intracellular hepatocyte cholesterol rises; this rising cholesterol stimulates PCSK9 gene transcription, increasing circulating PCSK9 protein; PCSK9 targets LDL receptors for lysosomal degradation, transiently reducing LDL receptor surface density and accelerating LDL-C accumulation in plasma. Together these mechanisms produce an acute vulnerability window supported by pharmacoepidemiological data showing sharply elevated recurrent MI and death rates in post-MI patients who discontinue statins.
Option B: Option B is incorrect because while HMG-CoA reductase upregulation does occur as a compensatory response during statin therapy, this does not produce LDL-C levels transiently 40 to 60% above the pre-statin baseline — the magnitude is exaggerated, and net LDL-C dynamics after discontinuation are driven primarily by the PCSK9-mediated receptor degradation component rather than by reductase overexpression alone.
Option C: Option C is incorrect because there is no established pharmacological rebound of thromboxane A2 above pre-treatment levels after statin discontinuation — statins' antithrombotic pleiotropic effects are lost upon withdrawal, but this is loss of a protective effect, not a synthesis rebound exceeding baseline; the analogy to aspirin discontinuation is not pharmacologically supported.
Option D: Option D is incorrect because cholesterol crystal embolization from acute plaque destabilization following statin withdrawal, while theoretically possible, is not a pharmacologically established or clinically predictable event within a fixed timeframe — this option overstates mechanistic certainty in a way unsupported by the evidence base.
Option E: Option E is incorrect because statin discontinuation risk is not entirely attributable to LDL-C rise alone — the loss of pleiotropic effects constitutes an independent and faster-acting mechanism that operates on a different timescale than LDL-C dynamics, and the overall risk profile after discontinuation is substantially more complex than the simple mirror image of initiation benefit.
8. A 44-year-old man received a kidney transplant 14 months ago. His initial immunosuppression included cyclosporine, which was transitioned to tacrolimus at 6 months; he is now maintained on tacrolimus and mycophenolate mofetil. His LDL-C is 148 mg/dL. Which statin choice is most pharmacologically appropriate in this patient's current immunosuppressive context?
A) Pravastatin at a reduced dose, because the extensive safety record of pravastatin in transplant recipients — established through its non-CYP metabolism and low OATP1B1 dependence — applies to this patient regardless of whether he is now on tacrolimus or cyclosporine, making pravastatin the single correct choice in any post-transplant patient
B) Simvastatin 20 mg, because its prodrug formulation requires hepatic activation before systemic distribution, meaning muscle toxicity cannot occur before the drug reaches its inactive form, which confers a unique safety advantage in patients on calcineurin inhibitors
C) Rosuvastatin 20 mg, which avoids the CYP3A4 pathway shared with tacrolimus, is not meaningfully affected by tacrolimus at therapeutic concentrations via OATP1B1, and achieves high-intensity LDL-C reduction appropriate for a patient with an LDL-C of 148 mg/dL in a post-transplant context where aggressive lipid management is indicated
D) All statins at any dose, because transitioning from cyclosporine to tacrolimus eliminates all pharmacokinetic interactions between calcineurin inhibitors and statins; tacrolimus has no interaction with any statin via CYP or transporter pathways, making agent selection and dosing equivalent to a patient without immunosuppression
E) Atorvastatin 20 mg, because its shared CYP3A4 metabolism with tacrolimus produces competitive enzyme inhibition that reduces both drug exposures simultaneously, lowering statin toxicity risk while also reducing tacrolimus-related nephrotoxicity
ANSWER: C
Rationale:
This question asked you to select the most appropriate statin for a transplant recipient who has been transitioned from cyclosporine to tacrolimus, testing knowledge of how these two calcineurin inhibitors differ pharmacokinetically and what those differences mean for statin selection. Cyclosporine is a potent inhibitor of both OATP1B1 and CYP3A4, producing dramatic increases in exposure for most statins and requiring either substantial dose reduction or substitution to agents with the least interaction — historically pravastatin and fluvastatin. Tacrolimus has a substantially different profile: it shares CYP3A4 metabolism with atorvastatin, simvastatin, and lovastatin but does not inhibit CYP3A4 to a clinically meaningful degree at therapeutic trough concentrations, and its effect on OATP1B1 is not equivalent to cyclosporine. In a patient now eight months beyond cyclosporine discontinuation and maintained on tacrolimus alone, the severe pharmacokinetic constraints associated with cyclosporine co-administration no longer apply. Rosuvastatin 20 mg is the most appropriate choice: its absence of CYP3A4 metabolism avoids the shared pathway with tacrolimus, its OATP1B1 dependence is not significantly affected by tacrolimus at therapeutic concentrations, and 20 mg achieves high-intensity LDL-C reduction appropriate for a patient with LDL-C of 148 mg/dL who warrants aggressive management.
Option A: Option A is incorrect because pravastatin's established safety record in transplant recipients was built specifically in the context of cyclosporine co-administration, where its non-CYP profile minimized the interaction that damages other statins; in a patient now on tacrolimus, pravastatin's lower LDL-C-lowering potency makes it a suboptimal choice when rosuvastatin offers equivalent or better interaction safety with superior efficacy.
Option B: Option B is incorrect because simvastatin's prodrug nature does not protect against muscle toxicity — the active hydroxy acid form circulates systemically and reaches skeletal muscle, and simvastatin's high CYP3A4 dependence makes it a high-interaction-risk agent in any patient receiving drugs that affect CYP3A4 metabolism.
Option D: Option D is incorrect because tacrolimus does not eliminate all statin interaction risk — while it lacks the potent OATP1B1 and CYP3A4 inhibition of cyclosporine, careful agent selection and monitoring remain appropriate in any transplant patient; this option overstates the pharmacokinetic neutrality of tacrolimus.
Option E: Option E is incorrect because the shared CYP3A4 metabolism of atorvastatin and tacrolimus does not produce mutual competitive inhibition that reduces both exposures — at clinically relevant concentrations, competitive inhibition between two substrates of the same enzyme does not predictably lower both exposures and does not reduce tacrolimus-related nephrotoxicity by this mechanism; this framing is pharmacologically inverted.
9. A 55-year-old man with stable coronary artery disease has been on atorvastatin 10 mg daily for two years, achieving an LDL-C of 101 mg/dL. His cardiologist cites the TNT trial as justification for intensifying therapy. The patient asks why a lower LDL-C is better if his current level is already considered normal. Which of the following best reflects the clinical evidence underlying the lower-is-better principle?
A) The lower-is-better principle applies only to patients with baseline LDL-C above 130 mg/dL; once LDL-C falls below 100 mg/dL on statin therapy, further reduction produces no additional event reduction because the atherosclerotic process becomes LDL-C-independent at these concentrations
B) The lower-is-better principle is supported by JUPITER rather than the TNT trial; TNT demonstrated benefit of atorvastatin 80 mg over 10 mg but achieved a mean LDL-C of only 98 mg/dL in the intensive arm, which does not support the sub-70 mg/dL targets now recommended in very-high-risk secondary prevention
C) Current guidelines do not recommend an LDL-C target below 100 mg/dL in secondary prevention patients because the adverse effect burden of high-intensity statin therapy outweighs any marginal event reduction below this threshold, and the TNT trial demonstrated unacceptable rates of hepatotoxicity at atorvastatin 80 mg
D) Very low LDL-C levels achievable with current therapies are associated with an inverse relationship in which further reduction paradoxically increases hemorrhagic stroke risk to a degree that offsets ischemic event reduction, establishing a U-shaped benefit curve with an optimal LDL-C of approximately 70 to 80 mg/dL
E) The TNT trial demonstrated that high-intensity atorvastatin 80 mg produced a 22% additional relative reduction in major cardiovascular events compared to atorvastatin 10 mg in patients with stable coronary disease, with mean achieved LDL-C of 77 versus 101 mg/dL, establishing that incremental LDL-C lowering below 100 mg/dL produces proportional incremental cardiovascular benefit with no apparent floor to the relationship
ANSWER: E
Rationale:
This question asked you to apply the TNT trial findings to the clinical question of incremental LDL-C lowering in a patient already below 100 mg/dL on moderate-intensity statin therapy. The Treating to New Targets (TNT, 2005) trial enrolled 10,001 patients with stable coronary artery disease and randomized them to atorvastatin 80 mg versus atorvastatin 10 mg, achieving mean LDL-C levels of 77 mg/dL and 101 mg/dL respectively. The high-intensity arm produced a 22% relative risk reduction in the primary composite endpoint of major cardiovascular events. TNT was foundational in establishing the lower-is-better principle: LDL-C lowering below 100 mg/dL produces proportional incremental event reduction with no apparent threshold below which benefit plateaus or disappears. The Cholesterol Treatment Trialists meta-analyses further established that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C produces a consistent 22% reduction in major vascular events regardless of baseline LDL-C — a log-linear, continuous, threshold-free relationship confirmed across 26 randomized trials involving 169,138 participants.
Option A: Option A is incorrect because the lower-is-better principle explicitly applies across the LDL-C range including values below 100 mg/dL — the CTT meta-analysis demonstrated consistent event reduction proportional to LDL-C change at every baseline level studied.
Option B: Option B is incorrect on factual grounds: TNT's intensive atorvastatin arm achieved a mean LDL-C of 77 mg/dL, which is squarely in the sub-80 mg/dL range — not 98 mg/dL; JUPITER enrolled primary prevention patients with a different clinical question.
Option C: Option C is incorrect because current ACC/AHA 2018 guidelines for very-high-risk secondary prevention patients explicitly recommend an LDL-C target below 70 mg/dL; TNT did not demonstrate unacceptable hepatotoxicity rates at atorvastatin 80 mg, and the adverse effect burden at guideline doses is considered acceptable in secondary prevention.
Option D: Option D is incorrect because while very low LDL-C has been associated with modest hemorrhagic stroke risk in some epidemiological cohorts, the randomized trial evidence including TNT, PROVE IT–TIMI 22, and FOURIER does not demonstrate a U-shaped benefit curve at LDL-C levels achievable with approved therapies — net clinical benefit strongly favors intensive LDL-C lowering in secondary prevention.
10. A 59-year-old woman with hypercholesterolemia and a 10-year ASCVD risk of 14% has tried atorvastatin 40 mg and rosuvastatin 20 mg on separate occasions, both producing intolerable myalgias that resolved within two weeks of discontinuation. Her LDL-C off statins is 162 mg/dL. She refuses further daily statin trials. Her physician proposes alternate-day rosuvastatin dosing. Which of the following best explains the pharmacological rationale for this strategy?
A) Alternate-day dosing of rosuvastatin achieves LDL-C reduction equivalent to daily dosing because compensatory HMG-CoA reductase upregulation on drug-free days is fully suppressed by a PCSK9 inhibitory effect of rosuvastatin that persists for 48 hours after each dose independently of plasma drug concentrations
B) Rosuvastatin's half-life of approximately 19 hours — the longest of any statin — combined with its high hepatoselectivity means that hepatocyte drug concentrations remain sufficient to maintain meaningful HMG-CoA reductase inhibition throughout a 48-hour dosing interval, supporting alternate-day or two-to-three-times-weekly dosing that achieves 20 to 30% LDL-C reduction in patients who cannot tolerate any daily dose
C) Alternate-day rosuvastatin works by avoiding peak plasma concentrations; because rosuvastatin myopathy risk is entirely concentration-dependent at peak levels, every-other-day dosing halves the number of peak exposure events and therefore precisely halves cumulative myopathy risk compared to daily dosing
D) Alternate-day rosuvastatin dosing is pharmacologically irrational because HMG-CoA reductase inhibition requires uninterrupted 24-hour enzyme suppression to prevent compensatory upregulation during drug-free intervals, making any schedule less frequent than daily therapeutically equivalent to no treatment
E) Alternate-day dosing is only appropriate when combined with high-dose ezetimibe because rosuvastatin's biliary excretion during drug-free days requires simultaneous intestinal cholesterol absorption blockade to prevent rebound hypercholesterolemia sufficient to negate cardiovascular benefit
ANSWER: B
Rationale:
This question asked you to apply pharmacokinetic properties of rosuvastatin to the management of statin intolerance through non-daily dosing. Rosuvastatin has a half-life of approximately 19 hours — the longest of any statin in clinical use; by comparison, simvastatin's active hydroxy acid form has a half-life of approximately 2 hours and atorvastatin's parent compound approximately 14 hours with active metabolites extending biological effect. Rosuvastatin is also highly hepatoselective: its liver-to-plasma concentration ratio strongly favors intrahepatic accumulation, meaning hepatocyte drug concentrations decline more slowly than plasma concentrations and remain measurably above the HMG-CoA reductase inhibitory threshold for a substantial portion of the 48-hour interval between alternate-day doses. Clinical data from multiple small trials of alternate-day and two-to-three-times-weekly rosuvastatin in statin-intolerant patients demonstrate LDL-C reductions of 20 to 30% from baseline — meaningfully better than no statin and, when combined with daily ezetimibe 10 mg, capable of achieving 40 to 50% LDL-C reduction comparable to moderate-intensity daily statin therapy. This strategy is endorsed in clinical practice guidance as a reasonable option for statin intolerance management.
Option A: Option A is incorrect because rosuvastatin does not possess PCSK9 inhibitory activity — PCSK9 inhibition is the mechanism of a distinct drug class (evolocumab, alirocumab); rosuvastatin lowers LDL-C exclusively through HMG-CoA reductase inhibition, and any PCSK9 fluctuations during statin therapy reflect upstream cholesterol homeostasis signaling, not direct drug action on PCSK9.
Option C: Option C is incorrect in its mechanistic framing: the pharmacological rationale for alternate-day dosing is maintenance of trough hepatocyte concentrations above the inhibitory threshold via the long half-life — not avoidance of peak plasma concentrations; and the claim that myopathy risk is entirely peak-concentration-dependent such that every-other-day dosing precisely halves cumulative risk is a quantitative oversimplification not supported by pharmacovigilance data.
Option D: Option D is incorrect because the premise of required uninterrupted 24-hour enzyme suppression is false; rosuvastatin's long half-life and tissue accumulation properties sustain meaningful reductase inhibition across a 48-hour dosing interval, which the clinical efficacy data for alternate-day dosing directly demonstrate.
Option E: Option E is incorrect because ezetimibe co-administration enhances but is not required for alternate-day rosuvastatin efficacy; there is no pharmacologically established rebound hypercholesterolemia of sufficient magnitude during rosuvastatin drug-free days to negate cardiovascular benefit, and the claim that high-dose ezetimibe is obligatory is unsupported — ezetimibe is dosed at 10 mg daily, and the strategy is viable without it.
11. A 66-year-old man with stable coronary artery disease is started on rosuvastatin 20 mg. Three days later, his wife reports that his exertional chest tightness has noticeably improved. His physician is skeptical, noting that meaningful LDL-C reduction typically requires 4 to 6 weeks. Which of the following best explains the pharmacological basis for early symptomatic improvement before significant LDL-C lowering has occurred?
A) The improvement is a placebo effect; all recognized pharmacological actions of statins — including endothelial, anti-inflammatory, and antithrombotic effects — require at least 4 to 6 weeks to become clinically detectable and are tightly coupled to the degree of LDL-C reduction achieved
B) Rosuvastatin achieves near-complete HMG-CoA reductase inhibition within 72 hours, producing a rapid fall in LDL particle number that precedes measurable LDL-C mass reduction; it is this early particle count reduction rather than LDL-C that produces immediate plaque stabilization and explains symptomatic benefit
C) Early symptomatic improvement is explained by the antithrombotic pleiotropic effect of statins: rosuvastatin inhibits thromboxane A2 synthase within 48 to 72 hours, completely eliminating platelet-mediated vasoconstriction in coronary vessels and producing an anti-ischemic effect equivalent to high-dose aspirin within the first week of therapy
D) Statins increase endothelial nitric oxide synthase (eNOS) expression and activity through inhibition of Rho GTPase prenylation — Rho GTPase normally destabilizes eNOS mRNA and suppresses its expression — producing improved endothelium-dependent vasodilation detectable within days of initiation; this early enhancement of coronary vasodilatory reserve can plausibly reduce exertional ischemic symptoms before meaningful LDL-C reduction occurs
E) Statin-mediated inhibition of fibrinogen synthesis reduces plasma viscosity within 72 hours of initiation; fibrinogen levels fall by 30 to 40%, reducing microvascular resistance in coronary arterioles and producing measurable improvement in coronary perfusion that precedes any change in LDL-C or atherosclerotic plaque
ANSWER: D
Rationale:
This question asked you to identify the pharmacological mechanism that can plausibly explain symptomatic improvement within days of statin initiation, before LDL-C reduction is meaningful. Statins inhibit the mevalonate pathway, reducing not only cholesterol synthesis but also production of the non-sterol isoprenoid intermediates farnesyl pyrophosphate and geranylgeranyl pyrophosphate. These isoprenoids are required for post-translational prenylation — membrane anchoring — of small GTP-binding proteins including Rho GTPase. Rho GTPase in its active, membrane-anchored form normally destabilizes eNOS mRNA through Rho-kinase-mediated signaling and reduces eNOS protein expression in vascular endothelium. When statin inhibition reduces Rho prenylation, the stabilizing restraint on eNOS is removed, eNOS expression and activity increase, and endothelial nitric oxide availability rises within days of initiation — well before any meaningful LDL-C reduction. In a patient with stable coronary artery disease and exertional angina, improved endothelium-dependent coronary vasodilation in response to exercise — mediated by increased eNOS-derived nitric oxide — can plausibly reduce the ischemic threshold and improve exertional symptoms. This is the pharmacologically most precise explanation available for early statin benefit in this clinical context.
Option A: Option A is incorrect because the pleiotropic endothelial effects of statins — including eNOS upregulation — are pharmacologically well-characterized and demonstrable within days of initiation, preceding and operating independently of LDL-C lowering; dismissing early improvement as pure placebo is pharmacologically inaccurate and clinically misleading.
Option B: Option B is incorrect because while LDL particle number may fall early and precede changes in LDL-C mass, plaque stabilization through LDL particle number reduction is not a mechanism that operates within 72 hours — plaque structural remodeling requires weeks to months of sustained lipid lowering; this option conflates biomarker kinetics with structural plaque change timelines.
Option C: Option C is incorrect because statins do not inhibit thromboxane A2 synthase — that is the mechanism of aspirin and other arachidonic acid pathway inhibitors; statins' antithrombotic effects are mediated through modest reductions in platelet aggregability and tissue factor expression, not through direct eicosanoid pathway enzyme inhibition, and the anti-ischemic effect is not equivalent to high-dose aspirin.
Option E: Option E is incorrect because while statins modestly reduce fibrinogen levels as part of their anti-inflammatory effects, the magnitude is not 30 to 40% and the timeline of 72 hours is not pharmacologically supported — fibrinogen reduction is a gradual and modest effect, not a rapid hemodynamic action sufficient to explain clinically meaningful improvement in coronary perfusion within days.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.